Compare WATT & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WATT | AKTX |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 14.4M |
| IPO Year | 2014 | N/A |
| Metric | WATT | AKTX |
|---|---|---|
| Price | $5.20 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.53 |
| AVG Volume (30 Days) | 406.5K | ★ 1.6M |
| Earning Date | 02-26-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,018,000.00 | N/A |
| Revenue This Year | $509.64 | N/A |
| Revenue Next Year | $210.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 600.23 | N/A |
| 52 Week Low | $3.62 | $0.22 |
| 52 Week High | $22.20 | $1.73 |
| Indicator | WATT | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 35.04 |
| Support Level | $4.80 | $0.28 |
| Resistance Level | $8.20 | $0.31 |
| Average True Range (ATR) | 0.69 | 0.03 |
| MACD | 0.21 | 0.01 |
| Stochastic Oscillator | 35.92 | 26.92 |
Energous Corp has developed wireless power networks technology (WPNT), consisting of semiconductor chipsets, software controls, hardware designs, and antennas, that enable radio frequency (RF) based charging for Internet of Things (IoT) devices. The WPN technology provides a comprehensive suite of capabilities designed to power the next generation of wireless energy networks, seamlessly delivering power and data across diverse, battery-free device ecosystems. It enhances operational visibility, control, and intelligent business automation. Its products include Transmitter IC & Module, Receivers IC, Transmitter System, and Evaluation Kits.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.